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ABSTRACT

OBJECTIVE: The objective of this systematic review is to determine whether or not proton
pump inhibitors are a safe and effective treatment for gastroesophageal reflux disease in infants
less than twelve months old.
STUDY DESIGN: Review of three English language primary studies published in 2003, 2007,
2009
DA TA SOURCES: Randomized, double blind, placebo controlled trials comparing proton pump
inhibitors to placebo were found using Ovid MEDLINE, and Cochrane databases.
OUTCOMES MEASURED: Gastroesophageal reflux disease symptoms in infants. Symptoms
include crying, irritability, vomiting, apnea, bradycardia, choking, and behavioral trials. One
trial used responder status, which is defined as a 2:50% reduction from baseline in either
percentages of feedings with crying episodes or duration (in minutes) of episodes averaged
across feedings. Another trial documented the cry/fuss time in minutes per 24 hour period.
Other outcomes include adverse events requiring treatment and serious adverse events requiring
hospitalization.
RESULTS: All three RCTs included in this review found that proton pump inhibitors were not
effective in reducing the symptoms of GERD in infants. There was no significant decrease
compared to control groups. One RCT showed a significant increase in the number of both
adverse events and serious adverse events compared to placebo groups.
CONCLUSIONS: Results of the RCTs reviewed demonstrate that proton pump inhibitors are
not a safe and effective treatment for gastroesophageal reflux disease in infants less than twelve
months old. Further research is warranted to determine the primary cause ofthese reflux
symptoms and to investigate transient lower esophageal sphincter relaxation.
KEY WORDS: proton pump inhibitors,

inf~mts
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INTRODUCTION

Gastroesophageal reflux disease (GERD) is a common disorder affecting persons of all
ages and is characterized by reflux of the gastric contents into the esophagus, causing
complications. Many infants under the age of one, including premature infants, experience
symptoms attributed to GERD. The principal treatment for symptomatic GERD in adults and
children is acid suppression. Proton pump inhibitors (PPI) have widespread use in adults and
children and are recognized as the most effective agents to suppress gastric acid secretion 2.
Although FDA indication for PPT use does not include patients less than one year old, there has
recently been an increasing amount of PPIs used for this age group to alleviate symptoms l .
GERD in infants is of major relevance to the scope of physician assistant practice.
Excessive crying is the most common reason for parents to seek medical help for newborns in
the first three months of life 2. It is hypothesized that gastroesophageal reflux is a frequent cause
of this irritability and crying. While GERD is usually a benign process in infants, significant
irritability of the child leads to increased concern of the parent and more frequent medical visits
and costs. If the irritability of the infant is related to reflux, then reduction in acid exposure by
highly effective proton pump inhibitors should reduce the symptoms. This logical hypothesis
has been put into practice, as demonstrated by the seven-fold increase in the use PPIs in infants
between 1999 and 2004 1• Because there is no FDA indication for PPI use in infants, the actual
amount of money spent on "off-label" use ofPPIs for this population is not well-documented or
readily available.
GERD is defined as symptoms or mucosal damage produced by the abnormal ret1ux of
gastric contents into the esophagus. The clinical symptoms of GERD in an infant differ from
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symptoms of an adult. The most common symptom of GERD in an infant is
regurgitation/vomiting 4. The additional symptoms in an infant are non-specific and include
excessive irritability and crying, failure to thrive, feed refusal, apnea, or aspiration pneumonia.
Preterm infants and newborns are at increased risk for GERD due to their immature musculature,
predominantly liquid diet and supine positioning while feeding. The principal mechanism of
acid reflux in infants is found to be transient lower esophageal sphincter relaxation3 . Moreover,
GERD in infants is associated with the development of serious chronic health issues such as
recurrent pneumonia, chronic cough, recurrent stridor and reactive airway disease 4.
The goals of therapy for GERD are to relieve symptoms, promote healing of esophagus,
and to prevent respiratory complications and recurrence of the disease. Treatment ofGERD in
children and adults includes antacids, pro-kinetic agents, and acid suppressants, such has
histamine H2 receptors and PPIs. Currently there are no therapies that target the transient
relaxation of the lower esophageal sphincter. In children over the age of one it has been found
that PPIs have superior efficacy over other treatments4 • Because no PPIs are approved for usage
in infants, conservative treatments and non-pharmacological management are attempted initially.
Feeding strategies include the use ofthickened or hypoallergenic formulas, frequent burping,
frequent small feedings, or dairy avoidance by breast-feeding. Because there is an increase in
reflux when supine, parents are encouraged to try to minimize supine positioning and vigorous
handling post-feeding. Additional simple conservative measures include increased parental
reassurance and smoking cessation I.
While the above treatments may be efiective, many infants do not respond to
conservative treatments. PPIs may provide satisfactory reduction of symptoms of GERD in
infants over other products and methods. Based on the findings that PPIs are the most
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efficacious GERD agents and that they are preferred treatment for children older than one, it is
proposed that they will be effective treatments in infants. Health care providers have been
recommending and prescribing PPIs for infants in an escalating amount. However, there is a
lack of sufficient evidence and reputable randomized controlled trials that demonstrate the
efficacy and safety of PPI use in this specific population.

OBJECTIVE:
The objective of this systematic review is to determine whether or not proton pump
inhibitors are a safe and effective treatment for gastroesophageal reflux disease in infants less
than twelve months old.

METHODS:
All three studies selected for this review met the following criteria. The population was
otherwise healthy infants, including premature infants, who were less than twelve months of age.
The interventions used in the studies were the administration of weight-based doses of proton
pump inhibitors, namely omeprazole and lanzoprazole. The main outcomes measured were
reduction of GERD symptoms, such as cry/fuss time, irritability, vomiting, choking, apnea, as
well as adverse events and serious adverse events. All of these outcomes qualify as patient
oriented evidence that matters (POEM). The studies were double blind, randomized and
placebo-controlled.
The author searched Ovid Medline and Cochrane Database of Systematic Reviews for
articles and RCTs using the keywords "proton pump inhibitors" and "infants". All articles in this
review were in English and published in peer-reviewed journals. All articles were selected based
on importance of outcomes to the patient (POEM). Inclusion criteria were studies that were
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randomized, controlled, prospective, based on patient oriented outcomes, and published after
1996. Exclusion criteria were articles that were published before 1996 and articles that focused
on patients over twelve months of age. The study perfomled by Orenstein et al took place at 16
centers, with 8 in the United States and 8 in Poland, between the dates of June 29,2006 and May
16, 2007. The studies performed by Moore et al and Omari et al were both conducted in
Australia. The statistics utilized in the studies were p values, number needed to harm (NNH),
relative risk increase (RRI), and absolute risk increase (ARl).
OUTCOMES MEASURED:

The outcomes addressed in the Orenstein 2009 study were responder status, adverse
events (AE) and serious adverse events (SAE). AEs were treatment emergent cases and SAEs
required hospitalization. Responder status is defined to be >50% reduction from baseline in
either percentages of feedings with crying episodes or duration (in minutes) of episodes averaged
across feedings. Responder rate was the percentage of participants who were responders at week
4. Outcomes were measured by documenting the daily number and duration of crying episodes
during or sl hour after feeding. AEs and SAEs were also documented.
The outcomes addressed in the Moore 2003 study were the cry/fuss time of the infant in a
24 hour period and the irritability of the child. The outcomes were measured by 1.) a diary in
which the parents recorded infant behavior including crying and fussing time and 2.) a visual
analog score 01A) ranging from 0-10 of parental impression of the level of infant irritability.
The outcomes addressed in the Omari 2007 study were symptom events that were
recorded on bedside symptom charts by neonatal nursery staff. Symptom events were classified

as vomiting, apnea, bradycardia, and behavioral changes.
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Table 1: Demographics of included studies
Study

Type

#Pt

Age

Inclusion
Criteria

Orenstein
2009 (1)

Double
blind
RCT

162

28 days
to <12
months;
pretenn
corrected
age 44
weeks
but <12
months

Weight >2.0 kg,
daily diary
documented
crying during or
within 1 hour 2:
25% of feeds
during 4 days of
randomization
despite 2:7 days of
non
pharmacologic
management

Moore,
2003 (2)

Double
blind
RCT

30

Omari,
2007 (3)

Double
blind
RCT

10

Exclusion
Criteria

Use ofPPI in
30 days, use
ofH2
antagonists in
7 days,
clinically
significant
disease,
esophageal
disease or
upper GI
anomaly,
requirements
of continuous
tube feedings
3-12
History of
Use ofPPI
months in spilling,
before
age
irritability and
recruitment,
crying; previously history of
given empirical
melena or
treatment for
hematemesis,
GERD; 24 hour
medical or
pH monitoring
surgical
reflux index (total condition
recording time
other than
with pH<4 in 24
GERD
hours) of>5%,
biopsy criteria for
esophagitis
Preterm
Preterm infants
<32 weeks
infants,
with symptoms of PMA,on
mean
GERD who did
CPAP or
post
not respond to
ventilation,
menstrual conservative
acute illness,
therapy, reflux
age of
neurologic
36.1
index >5%
disease,
weeks,
hepatic/
mean
renal
postnatal
impainnent,
age 50
bone marrow
days
abnormality

WD

Intervention

64

Lansoprazole 1 x
daily x 4 weeks.
Dosages:
0.2 to 0.3
mg/kglday for
infants :s 10
weeks of age;
1.0 to 1.5
mg/kglday for
infants >10
weeks of age

4

Omeprazole:
Infants weighing
5-10 kg were
given 10 mg
daily x 2 weeks;
infants> 10 kg
were given 10
mgBTD x 2
weeks

0

Omeprazole 0.7
mg/kg added to 2
mLlkg of antacid
Mylanta given in
NG tube to
infant
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RESULTS
The Orenstein 2009 study compared the efficacy of PPI lansoprazole versus placebo for
the reduction of GERD symptoms as shown in Table 2. Lansoprazole and placebo produced
identical responder numbers (54%). Both the relative benefit increase and absolute benefit
increase are zero, which produced an unreal number for number needed to treat. Interestingly,
responder rates were greater in patients who continued with non-pharmacological management
into the double-blind period (63%) compared those who did not (19%). This study included
rates for compliance with medication (93% for PPI vs. 95% for placebo) and diary recordings
(96% PPI vs. 95% placebo).

Table 2: Efficacy of )ansoprazo)e vs. placebo for reduction of GERD symptoms, Orenstein 2009

Primary efficacy: Responder rate,
n(%)
Discontinued due to non-efficacy,
n (%)
Compliance
> 90% for drug, % of sub.iects
2: 90% for daily diary, % of
subjects
Global Severity assessment §
By parent: Improvement at
week 4
By physician: improvement at
week 4
Individual Symptoms
Cry, % of feeds/ week
Re2ur2itate, % of feedsl week
Stop feed soon, % of
feeds/week
Feed refusal, % of days/week
Archin2 back, % of day_s/week
Cou2hin2, % of days/week
Wheezing, % of days/week
Hoarseness

Lansoprazole
double-blind
(:54 weeks,
n=81)*
44 (54%)

Placebo doubleblind, (:54
weeks, n=81)*

P
value

Lansoprazole
open label
(1-3 weeks,
n=55) *

44 (54%)

NS

NA

28 (35%)

29 (36%)

NS

0

93%
96%

95%
100%

-

-

98%
93%

45 (56%)

41 (51%)

NS

44 (80%)

40 (49%)

NS

47 (85%)

-20
-14
-7

-20

NS
NS
NS

-19
-20
-3

-14
-20
0
-5

-10
-18

2

-5

NS
NS
NS
NS
NS

-15
-33
-3
-12
-9

44

(55%)~

-11

-8

-9
-6
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NS, not significant; NA, not applicable
*For subjects withdrawn from double-blind treatment before the 4th week, the last week of available data
is carried forward to the 4th week for the individual symptoms and GAs. The open label treatment ranged
from 1-3 weeks, depending on the time of withdrawal from the double-blind treatment; the final week of
open label data is summarized.
§Improved at least 1 severity level compared to baseline assessment
,nata missing from 1 subject: 44/80 (54%)

Assessing the safety of this drug class for this age group and population is a high priority
of this systematic review. The Orenstein 2009 study demonstrated that there are some safety
concerns, as illustrated in Table 3. There were more treatment emergent adverse events in the
lansoprazole-treated subjects than the placebo group (62% vs. 46% respectively). Of the
subjects who continued with open-label treatment with lansoprazole, 62% experienced AEs.
AEs were mostly mild or moderate and include (in descending order of frequency of
occurrence): upper respiratory infections, constipation and GERD, dermatitis and eczema, ear
infections, fever, lower respiratory infections, respiratory tract congestion, rhinorrhea,
candidiasis, diarrhea (excluding infective), vomiting, alkaline phosphatase increase, and viral
infection. The p-value of 0.058 was deemed as not significant. The relative risk increase (RR!)
and absolute risk increase (ART) were 35% and 16%, respectively. The numbers needed to harm

(NNH) is 7.
Serious AEs (SAEs) during the double-blind treatment were significantly more frequent
in the lansoprazole group compared to placebo (12% vs. 2%). The p-value is 0.032 which
indicates clinical significance. Number needed to harm is 10 patients and the RR! and ARI are
5% and 10%, respectively. All patients with SAEs were hospitalized and no deaths occurred.
SAEs include the following medical conditions in descending order of frequency: lower
respiratory infections, diarrhea, ileus, dehydration, ear infection (otitis media), upper respiratory
infections, epididymal infection, arachnoid cyst, cellulitis, febrile convulsion, and Klebsiella
infection. Orenstein et al reported that no SAE was identified as being directly treatment-related.
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Table 3: Adverse events of the Orenstein 2009 study comparing lansoprazole to placebo

Lansoprazole Placebo
double blind double
(n=81)
blind
(n=81)

P value*

Lanzoprazole
open label
(n=55)

RRI

ARI

NNH

AE collection
weeks, median,
range'

8.3, 1-9

8.3 , 1-9

NS

7.3, 5-8

-

-

-

AE

50 (62%)

35%

16%

7

10 (12%)

NS
(p=0.058)
0.032

11 (20%)

SAEs

17
(21%)
2 (2%)

2 (4%)

5%

10%

10

NS, not significant; RRI, relative risk increase; ARl, absolute risk increase; NNH, numbers needed to
harm
*Double blind treatment comparisons: Fisher exact test for AE percentage; Wilcoxon test for weeks of
AE collection
~or the double blind period, "collection weeks" includes 30 days posttreatment for those subjects who
did not enter open label treatment. For open label period this includes 20 days posttreatment for all
subjects who entered open-label treatment.

The outcomes measures in the Moore 2003 study were cry fuss time in minutes/24 hours
and a parental visual analog score. Results are shown in Tables 4 and 5. Period 1 and period 2
denotes the first two weeks and second two weeks of the trial, respectively. There was no
significant difference in the cry/fuss time while taking either omeprazole or placebo (191 vs.
200, P=0.400), nor was there a significant difference in cry/fuss time between period 1 and 2
(P=0.330). There was a significant decrease in cry/fuss time from baseline to period 1 (267 vs.
203, P= 0.040) and from baseline to period 2 (267 vs. 188, P=0.008). In an analysis of treatment
order (subjects who initiated with omeprazole vs. subjects who initiated with placebo group)
there was no difference in cry/fuss time from baseline (P=0.481), period 1 (P=0.604), or period 2
(P=0.534).
The visual analog device was a double sided slide rule with the side facing the parent
showing two extremes of "no irritability" and "worst irritability" and the side facing the

Smith M., PPI Use in Infants 9
investigator showing a linear scale of 0 to 10. The V A score while taking omeprazole or placebo
was not significantly different (5.0 vs. 5.9, P=0.214). While there was not a remarkable decrease
in the VA score between baseline and period 1 or between period 1 and 2, there was a significant
decrease between baseline and period 2 (6.8 vs. 4.8, P=0.008). In an analysis of treatment order,
there was no significant difference in VA score from baseline (p= 0.262), period 1 (p=0.724), or
period 2 (p=0.1 05). The data provided in Moore 2003 study is on a continuous scale and could
not be converted dichotomously to directly answer whether or not there was a treatment effect.

Tabl e 4 C;ry fu ss data m response to treat ment WI omeprazo e or pl aceb0, Moore 200~-'
Cry fuss time in min/24 hr (mean ± SD)
Baseline
Period 1
246±}05
203 ±113
Omeprazole (n=lS)
Placebo (n=lS)
287±132
204±87
267±1l9
203±99
Total (n=30)
*Mean of the combined data from Period 1 and Period 2 (n=30)
Baseline vs. Period 1, P=0.040
Baseline vs. Period 2, P=0.008

Period 2
179±129
198±115
188±121

Combined*
191±120
201±100

Table 5: Visual analog score by parents of the level of infant irritability in response to treatment
IbM
WI·th omeprazo1e or place
0, oore 2003
Visual analogue scale of infant irritability mean ± SD)
Combined*
Baseline
Period 1
Period 2
7.1±1.4
5.9 ±2.6
5.0±3.1
4.0±3.3
Omeprazole (n=lS)
6.0±2.1
5.9±2.1
6.6±1.7
5.7±2.2
Placebo (n=lS)
6.8±1.6
6.0±2.3
4.8±2.9
Total (n=30)
*Mean of the combined data from Period 1 and Period 2 (n=30)
Baseline vs. Period 2, P=0.008
The Omari 2007 study demonstrated through esophageal pH monitoring that omeprazole
therapy significantly reduced gastric acidity, esophageal acid exposure and the number and
duration of acid reflux episodes compared to placeb03 . However, the PPI did not demonstrate a
significant change in the number of symptomatic events that are attributed to GER, as illustrated
in Table 6. The treatment effect cannot be calculated based on the continuous data that was
gIven.
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Table 6: Effect of omeprazole on GER symptoms in preterm infants, Omari 2007
Symptoms

Frequency (number of events)
Placebo week
Omeprazole week
Vomiting
8.5 (7,22.8)
6.5 (3, 14.3)
Apnea
0.4 (0, 1.5)
1 (0, 1.8)
7.5 (1.3, 17.3)
Bradycardia
6.5 (3, 16)
0(0, 1)
0(0, 1.8)
Choking
17 (8.3, 27.8)
16.5 (7.3,30.1)
Behavioral changes
Data is presented as mean ± SEM or median (interquartile range).
DISCUSSION
Proton pump inhibitors have attained the FDA approval for children one year and older
and adults for short term treatment of symptomatic GERD and healing and symptomatic relief of
all grades of erosive esophagitis. The only contraindication is sensitivity to prior PPIs or any
component of the medication. The many available forms ofPPls include as a prescription,
generic, and over the counter medication, such as Prevacid OTe (lansoprazole). PPIs have
recently been in the medical news for their possible interactions with clopidogrel and the
possible increase risk of fractures of hip, wrist, and spine; however, these circumstances do not
directly apply to a patient population of infants. Pediatric Lexicomp Online states the uses and
possible doses of lansoprazole for infants beginning at three months of age. Most importantly,
Lexicomp found it necessary to note that treatment of GERD in children less than twelve months
old is controversial based on the findings of the Orenstein 2009 trial.
There were noteworthy limitations to these studies. Firstly, crying is nonspecific to
GERD; the coexistence of crying and reflux does not establish a causal relation. Behaviors that
are thought to be reflux related also occur in infants independent of acid reflux episodes.
Secondly, there may have been some variability with the outcomes data. Although all three
studies' outcomes were concerned with the subjects' reduction of symptoms, they were
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measured and recorded differently. It would have proven to be a more accurate comparison of
the three studies if the outcomes were measured identically. For example, Orenstein 2009 study
dealt with responder status and adverse events while Omari 2007 focused on symptoms observed
and documented by nursing staff. Additionally, limitations regarding treatment could have
included dosing, duration, or appropriate target. Orenstein 2009 study allowed subjects to enter
an open label treatment after only one week of double blind treatment, which may have
decreased the double blind response rate. Similarly, Omari 2007 subjects were only on the PPI
and placebo for one week each while Moore 2005 trial lasted 4 weeks.
Finally the Moore 2005 study suggested that infant irritability can improve with time,
independent of treatment. For both the cry/fuss time and VA score there was a significant
decrease between baseline and period 2. If the primary mechanism for reflux in an infant is
transient relaxation of lower esophageal sphincter, then it would be logical to postulate that as
the muscle tone of sphincter increases with age, the symptoms of GERD should subside.
CONCLUSION
Proton pump inhibitors are not a safe and effective treatment for gastroesophageal reflux
disease in infants less than 12 months old. Although the PPIs may have reduced the gastric and
esophageal acidity, none of the trials showed a reduction in symptoms such as crying and
irritability. In addition, placing infants on PPIs may put them at increased risk for adverse
events. Future trials are warranted to investigate the primary cause of reflux symptoms in
infants. It would be interesting to perform manometry of the lower esophageal sphincter to
determine if relaxation of the sphincter can be attributed for the reflux. Serial esophageal
manometry could establish if the strength of the sphincter increases with age and development,
resulting in reduction of symptoms of GERD.
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